Premium
Neuropharmacology in Pediatric Brain Injury: A Review
Author(s) -
Pangilinan Percival H.,
GiacolettiArgento Angela,
Shellhaas Renee,
Hurvitz Edward A.,
Hornyak Joseph Edward
Publication year - 2010
Publication title -
pmandr
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.617
H-Index - 66
eISSN - 1934-1563
pISSN - 1934-1482
DOI - 10.1016/j.pmrj.2010.07.007
Subject(s) - traumatic brain injury , medicine , neuropharmacology , population , neuroprotection , psychiatry , depression (economics) , intensive care medicine , pharmacology , environmental health , economics , macroeconomics
In this review, the current evidence is examined regarding neuropharmacologic treatment for children and adolescents (under the age of 18 years) who sustained a traumatic brain injury (TBI). Although the focus is on the pediatric TBI population, there is a paucity of empirical data related to the role of medication with children and adolescents after brain injury. Therefore, findings from the adult TBI literature are incorporated where appropriate so as to identify potential agents that warrant further examination in pediatric populations. This review addresses specific sequelae of TBI from the earliest stages of neurologic recovery to long‐term comorbidities, including disorders of impaired consciousness, post‐TBI agitation, cognitive decline, and post‐TBI depression. The evidence regarding the role of medication in neuroprotection and neurorecovery in this population is also explored. Medication classes reviewed include excitatory amino acids, antagonists to the N‐methyl‐D‐aspartate receptor, dopamine agonists, benzodiazepines, β‐blockers, anticonvulsants, and antidepressants. It is hoped that this review will guide future research, and ideas as to how this may be accomplished within a pediatric population are suggested.